Nanoparticle Advancement Shows Promising Action Against Prostate Cancer

Release Date: 24-Sep-2019

Prostate cancer is one of the leading cancers worldwide. About 11% men will face prostate cancer in their lifetime. Most of the traditional treatments such as chemotherapy, surgery and radiation can have fetal adverse effects. The Researchers at Rice University, Duke University and Mount Sinai recently perform a study, which involves testing a medical device from Nanospectra Bioscience called AuroLase Therapy that shows intense improvement in treatment with few of the side effects. The therapy was invented at Rice University.


According to the study lead author Ardeshir Rastinehad, Gold silica nanoshell infusion allows for a focused therapy that is able to treat the cancer while sparing the rest of the prostate, thus preserving a patient’s quality of life by reducing unwanted side effects, which could include erectile dysfunction or leakage of urine.   


This research was published in the journal roceedings of the National Academy of Science (PANS). The trail involves a group of 16 men of age grouyp of about 58 to 79years. They are suffering from low to intermediate risk localised prostate cancer. 15 out of 16 received the two-day treatment, which involved an intravenous infusion of nanoparticles on the first day followed the next day by an image-guided ablation treatment.


After the treatment with the nanoparticle, all patients went home, returning for follow-up tests at three- month, six-month, and one-year intervals.  From the 15 patient, about 2 patients had detected cancer in biopsies and MRI diagnosis within one year. The clinical trial is continuing and about 44 patients have been treated at Mount Saini and two other clinical locations in Michigan and Texas.


The particles are minuscule silica spheres with a outer coating of gold. The particle is termed as called nanoshells. They are about 50 times smaller than a red blood cell. They were invented by Rice University engineer and nanoscientist Naomi Halas in 1997. They are produced by altering the thickness of the gold coating.


AuroLase was approved by the food and drug administration of the US. They approved Aurolase therapy as a medical device. The clinical trials related to AuraLase shows its effectiveness in late stage neck and lung cancer. In 2011, advancements in medical imaging take place and nanoshell combines with the ultrasound and MRI. It shows its effects in prostate cancer also.


According to the lead author, this first-in-human pilot device study suggests that GSN-directed laser excitation and ablation is a safe and technically feasible procedure for the targeted thermal destruction of prostate tumors, and I am very excited to be part of this new frontier in nanomedicine.


Need custom market research solution? We can help you with that too.